logo
Say cheese: a smile is more attractive than the effects of Botox

Say cheese: a smile is more attractive than the effects of Botox

Times06-06-2025

Act now to keep your subscription
We've tried to contact you several times as we haven't been able to take payment. You must update your payment details via My Account or by clicking update payment details to keep your subscription.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Map reveals where being outdoors during the summer could kill you in a matter of minutes... are you at risk?
Map reveals where being outdoors during the summer could kill you in a matter of minutes... are you at risk?

Daily Mail​

time42 minutes ago

  • Daily Mail​

Map reveals where being outdoors during the summer could kill you in a matter of minutes... are you at risk?

Experts are sounding the alarm over the hotter-than-average weather making its way across the US - warning that exposure to these temperatures could lead to life-threatening health complications. The US is currently experiencing a 'heat dome, which occurs when the atmosphere traps hot air over certain areas like a lid on a pot. It's ripping through the Midwest and Northeast, with temperatures expected to reach 100 degrees Fahrenheit - and at temperatures this high, deadly heat stroke could strike in under 15 minutes But temperature is only one part of the equation - the UV index is also important. The ultraviolet index is a measurement of the strength of sunburn-producing UV radiation - it indicates how strong the sun's UV rays are. The higher the index, the stronger the rays. Zero to two indicates there is minimal danger from the sun, but an index of just three to five is considered risky and people are advised to wear sun protection, such as sunscreen, sunglasses, a hat and sun-protective clothing. At a six or seven, there is moderate risk of harm from unprotected sun exposure. Eight to 10 indicates high risk and people may experience burns in under 10 minutes. Anything 11 or above is very high risk and people with fair skin can experience dangerous burns in just five minutes. People are advised to stay indoors or avoid the sun completely. And this summer - millions of Americans will experience these dangerously high levels. There is no end limit on the scale, as it is measured based on what can cause burns to people and can continue to increase as temperatures rise and the sun's rays become stronger. According to the EPA, every American is expected to be exposed to high temperatures this summer. Even Alaska has issued its first-ever heat warning this week, though its UV levels are still low. However, some are more at risk of life-threatening complications. Based on average indices recorded between 2006 and 2023, people in the southwest are expected to experience UV levels ranging from 10 to 13 and beyond. In June, western and eastern Texas, along with much of New Mexico, Colorado and Hawaii, as well as eastern Arizona will see indices of 12 to 13. Southern California, Nevada and Utah and western Arizona, as well as parts of Wyoming, Kanas, Oklahoma, Mississippi, Alabama, and Georgia will see a UV index of 11 or 12. All of Florida and nearly everyone in Louisiana will also experience UV levels of 11 to 12. As the summer progresses, UV indices of 12 to 13 will reach southern Florida and parts of California. And higher levels - seven to nine - will begin creeping north, reaching Washington, Oregon, Montana, the Dakotas, Wisconsin, Michigan, Ohio, Pennsylvania, New Jersey, New York and Maine. In August, levels will begin to dip a bit - decreasing to slightly lower levels than June. High UV exposure can lead to sunburns, which may blister and scar. Blistering that breaks the skin may increase the risk of infection, as bacteria and other contaminants can enter the area. UV exposure is also the leading cause of skin cancer, which strikes 5.4million Americans every year. And the risk of getting its deadliest form, melanoma, doubles after getting just five - or more - sunburns in your lifetime. Researchers believe UV indices are increasing because the ozone layer, which absorbs most of the suns UV rays, is depleting due to increased greenhouse gas commissions.

Stanley Cup-winning hockey stars try to hook teammate up with stunning model Sommer Ray amid celebrations
Stanley Cup-winning hockey stars try to hook teammate up with stunning model Sommer Ray amid celebrations

Daily Mail​

timean hour ago

  • Daily Mail​

Stanley Cup-winning hockey stars try to hook teammate up with stunning model Sommer Ray amid celebrations

The Florida Panthers are using their Stanley Cup success to try and seal a high-profile girlfriend for one of their teammates... and it's all playing out for the whole world to see. The Panthers sealed back-to-back titles with a 4-2 series win over the Edmonton Oilers on Tuesday night, and it has been wall-to-wall partying for the players ever since. Amid the wild celebrations, star man Matthew Tkachuk took to social media in a bold bid to try and hook up his teammate Anton Lundell with a girl: none other than DJ and model Sommer Ray. The situation all began to unfold when another of the Florida players - Sasha Barkov - brought Ray, 28, into the conversation on an Instagram Live stream. While wearing the uniform of another of his teammates, Sam Reinhart, Barkov revealed that he has 'two names on my Instagram search'. Revealing more, he said: 'Sommer Ray and Sam Reinhart. But one is by mistake. I typed Sommer Ray because I was trying to type Sam Reinhart.' A few hours later, the model was clearly still on the lips of the team, as Tkachuk took to X to shoot his shot for a young teammate. He wrote: 'Sorry for bothering you @SommerRay... but our friend Anton Lundell says hi!! Great guy' The hilarious exchange all unfolded on Friday night and as of Sunday morning, Ray is yet to respond - despite her comments section being flooded with Panthers fans trying to help out their man. Panthers players, meanwhile, are preparing for yet another parade through the streets of Florida, and it would be no surprise to see Ray mentioned again during the next set of celebrations. The DJ recently went viral after it emerged she had turned down an eyewatering $40million to join OnlyFans during Covid. Speaking on YouTuber George Janko's podcast, she said: 'In that time it was like, every single person in my life was coming to me and telling me, "Sommer, if you don't start an OnlyFans, you're stupid, you're stupid",' she said. '"Like how could you not do that?" 'The money I could make would be insane. Someone was saying, in that time with COVID... they said I could have made $40million or something like that.' Despite her insistence on not joining the adult content website, Ray is not doing badly on her own, with her net worth recently valued at around $8m. Lundell, meanwhile, is currently on a six-year, $30m deal with the Panthers, and he received a signing bonus of $2.5m this time last year.

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

Reuters

time2 hours ago

  • Reuters

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

June 22 (Reuters) - Novo Nordisk ( opens new tab on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen. The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine. In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients. In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group. "Everything was in line with what we expected," Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters. The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group. Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. "Those patients on lower doses actually had higher weight loss reduction," she said. "We've not really seen that before because we have not had powerful treatments that have got people close to target." CagriSema is a weekly injection that combines Novo's blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin. The CagriSema Phase 3 trial results "compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class," Dr. Davies said. Eli Lilly's (LLY.N), opens new tab tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks. Dr. Davies said it makes sense to have more options for patients, including "theoretical benefits" with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body's metabolic adaptation to weight loss, she said. Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026. "We expect to see approval maybe around the beginning of 2027," Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes. Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. "This also allows them to lose their body weight at a pace that isn't too steep. It also mitigates side effects," he said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store